Patents Assigned to Genelabs Technologies, Inc.
-
Patent number: 5824649Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: October 20, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5824507Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
-
Patent number: 5821091Abstract: A method of identifying the presence of activated T-cells in a sample containing a plurality of different cell types is disclosed. The method includes the detection of polynucleotide sequences selectively expressed in activated T-cells.Type: GrantFiled: January 26, 1996Date of Patent: October 13, 1998Assignee: Genelabs Technologies, Inc.Inventor: Gregory Dolganov
-
Patent number: 5814441Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.Type: GrantFiled: June 7, 1995Date of Patent: September 29, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Kenneth G. Hadlock
-
Patent number: 5789559Abstract: Nucleic acid sequences derived from enterically transmitted nonA/nonB viral hepatitis agent (HEV) are disclosed. DNA sequences encoding specific epitopes within viral protein sequences that are reactive with sera of individuals infected with different strains of HEV are also disclosed. These DNA sequences and fragments thereof are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, for example by using specific amplification of virus-derived DNA sequences, as well as for producing viral proteins or polypeptides.Type: GrantFiled: July 25, 1994Date of Patent: August 4, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5770689Abstract: An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.Type: GrantFiled: June 7, 1995Date of Patent: June 23, 1998Assignees: Genelabs Technologies, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Patent number: 5766840Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.Type: GrantFiled: June 5, 1995Date of Patent: June 16, 1998Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
-
Patent number: 5766916Abstract: The protease necessary for polyprotein processing in Hepatitis G virus (HGV) is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HGV.Type: GrantFiled: April 24, 1996Date of Patent: June 16, 1998Assignee: Genelabs Technologies, Inc.Inventors: Alexander S. Belyaev, Susan M. Chong
-
Patent number: 5763572Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.Type: GrantFiled: June 7, 1995Date of Patent: June 9, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Kenneth G. Hadlock
-
Patent number: 5744131Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5741490Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: GrantFiled: June 13, 1994Date of Patent: April 21, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice D. Yarbough
-
Patent number: 5738990Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: April 14, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5726014Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: September 17, 1993Date of Patent: March 10, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin
-
Patent number: 5716780Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: June 7, 1995Date of Patent: February 10, 1998Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5693463Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.Type: GrantFiled: December 23, 1992Date of Patent: December 2, 1997Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
-
Patent number: 5686239Abstract: Peptide antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV derived peptides and in particular, SG3, are immunoreactive with sera from individuals infected with HEV. The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV.Type: GrantFiled: May 9, 1994Date of Patent: November 11, 1997Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Albert W. Tam, Patrice O. Yarbough
-
Patent number: 5643714Abstract: Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.Type: GrantFiled: February 5, 1993Date of Patent: July 1, 1997Assignees: Genelabs Technologies, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kenneth G. Hadlock, Chin-Joo Goh, Steven K.H. Foung
-
Patent number: 5614366Abstract: Novel HTLV-I and HTLV-II peptide antigens are disclosed for use in diagnostics assays for screening and confirming HTLV-I and HTLV-II antisera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp46 envelope proteins, and are differentiated by their immunoreactivity with an HTLV-II specific monoclonal antibody and by HTLV-I and HTLV-II antisera. The peptides are also useful in vaccine compositions.Type: GrantFiled: February 8, 1991Date of Patent: March 25, 1997Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Kenneth G. Hadlock
-
Patent number: 5578444Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: December 20, 1993Date of Patent: November 26, 1996Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 5538865Abstract: Peptide antigens which are immunoreactive with sera from individuals infected with hepatitis C virus (HCV) are disclosed. Several of the antigens are immunologically reactive with antibodies present in individuals identified as having chronic and acute HCV infection. The antigens are useful in diagnostic methods for detecting HCV infection in humans. Also disclosed are corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic peptides.Type: GrantFiled: January 19, 1994Date of Patent: July 23, 1996Assignee: Genelabs Technologies, Inc.Inventors: Gregory Reyes, Jungsuh P. Kim, Randolph Moeckli